Lectin-binding characterizes the healthy human skeletal muscle glycophenotype and identifies disease-specific changes in dystrophic muscle

Altered expression of ganglioside GM3 molecular species and a potential regulatory role during myoblast differentiation

(2017) Shinji Go et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging Pharmacotherapies

(2017) Andrea M. Reinig et al.   PHARMACOTHERAPY

Eteplirsen in the treatment of Duchenne muscular dystrophy

(2017) Kenji Rowel Lim et al.   Drug Design Development and Therapy

B4GALNT2 (GALGT2) Gene Therapy Reduces Skeletal Muscle Pathology in the FKRP P448L Mouse Model of Limb Girdle Muscular Dystrophy 2I

(2016) Paul J. Thomas et al.   AMERICAN JOURNAL OF PATHOLOGY

Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy

(2016) Jerry R. Mendell et al.   ANNALS OF NEUROLOGY

A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells

(2016) Courtney S. Young et al.   Cell Stem Cell

Differentiation-related glycan epitopes identify discrete domains of the muscle glycocalyx

(2016) Brian J McMorran et al.   GLYCOBIOLOGY

Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial

(2016) Craig Campbell et al.   MUSCLE & NERVE

Structural basis of laminin binding to the LARGE glycans on dystroglycan

(2016) David C Briggs et al.   Nature Chemical Biology

Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy

(2016) Valeria Ricotti et al.   PLoS One

Matriglycan: a novel polysaccharide that links dystroglycan to the basement membrane

(2015) T. Yoshida-Moriguchi et al.   GLYCOBIOLOGY

Second-generation compound for the modulation of utrophin in the therapy of DMD

(2015) Simon Guiraud et al.   HUMAN MOLECULAR GENETICS

The potential of sarcospan in adhesion complex replacement therapeutics for the treatment of muscular dystrophy

(2013) Jamie L. Marshall et al.   FEBS Journal

Laminin-211 in skeletal muscle function

(2013) Johan Holmberg et al.   Cell Adhesion & Migration

High Throughput Screening for Compounds That Alter Muscle Cell Glycosylation Identifies New Role forN-Glycans in Regulating Sarcolemmal Protein Abundance and Laminin Binding

(2012) Paula V. Cabrera et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Sarcospan-dependent Akt activation is required for utrophin expression and muscle regeneration

(2012) Jamie L. Marshall et al.   JOURNAL OF CELL BIOLOGY

Decreased surface sialic acid content is a sensitive indicator of muscle damage

(2012) Yuko Iwata et al.   MUSCLE & NERVE

Dystroglycan Function Requires Xylosyl- and Glucuronyltransferase Activities of LARGE

(2012) K.-i. Inamori et al.   SCIENCE

Like-acetylglucosaminyltransferase (LARGE)-dependent modification of dystroglycan at Thr-317/319 is required for laminin binding and arenavirus infection

(2011) Y. Hara et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders

(2011) Kamel Mamchaoui et al.   Skeletal Muscle

O-Mannosyl Phosphorylation of Alpha-Dystroglycan Is Required for Laminin Binding

(2010) T. Yoshida-Moriguchi et al.   SCIENCE

Overexpression of Galgt2 Reduces Dystrophic Pathology in the Skeletal Muscles of Alpha Sarcoglycan-Deficient Mice

(2009) Rui Xu et al.   AMERICAN JOURNAL OF PATHOLOGY

The Mouse C2C12 Myoblast Cell SurfaceN-Linked Glycoproteome

(2009) Rebekah L. Gundry et al.   MOLECULAR & CELLULAR PROTEOMICS

The synaptic CT carbohydrate modulates binding and expression of extracellular matrix proteins in skeletal muscle: Partial dependence on utrophin

(2009) Jung Hae Yoon et al.   MOLECULAR AND CELLULAR NEUROSCIENCE